Two-thirds of toddlers with peanut allergy who used the VIASKIN Peanut patch from DBV Technologies completed an oral food ...

demonstrating continued efficacy of the VIASKIN Peanut patch in toddlers aged 1-3 years. The data show sustained improvement in treatment benefit after 36 months of treatment. Key findings from ...

The company also said a biologics license application for the toddlers' indication of the Viaskin Peanut Patch is expected to be submitted in the second half of 2026. Write to Stephen Nakrosis at ...

Researchers are hopeful that a small skin patch placed between the shoulders will help combat peanut allergies in young children. According to a study published this week in The New England ...

On Wednesday, DBV Technologies SA (NASDAQ:DBVT) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has outlined a clear ...

DBV Technologies' primary focus remains on the development of Viaskin Peanut, a therapeutic patch designed to protect against peanut allergies. The company has made significant strides in its ...

Furthermore, the alignment with the FDA on patch wear time methodology suggests ... that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development ...

DBV Technologies' primary focus remains on the development of Viaskin Peanut, a therapeutic patch designed to protect against peanut allergies. The company has made significant strides in its clinical ...